Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics
William Ang, Travis D. Kerr, Ananya Kodiboyena, Cristina Valero, Joris L. Vos, Vladimir Makarov, Alex A. Adjei, Luc G.T. Morris, Stephanie L. Schmit, Natalie L. Silver, Sujata Patil, Daniel J. McGrail
William Ang, Travis D. Kerr, Ananya Kodiboyena, Cristina Valero, Joris L. Vos, Vladimir Makarov, Alex A. Adjei, Luc G.T. Morris, Stephanie L. Schmit, Natalie L. Silver, Sujata Patil, Daniel J. McGrail
View: Text | PDF
Research Letter Oncology Public Health

Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographics

  • Text
  • PDF
Abstract

Authors

William Ang, Travis D. Kerr, Ananya Kodiboyena, Cristina Valero, Joris L. Vos, Vladimir Makarov, Alex A. Adjei, Luc G.T. Morris, Stephanie L. Schmit, Natalie L. Silver, Sujata Patil, Daniel J. McGrail

×

Figure 1

NLR varies in magnitude and prognostic relevance by patient race/ethnicity and sex.

Options: View larger image (or click on image) Download as PowerPoint
NLR varies in magnitude and prognostic relevance by patient race/ethnici...
(A and B) Univariable (A) and multivariable (B) regression model between indicated variables and log2(NLR). N = 8,095. Box-and-whisker plots show the regression coefficient with 95% confidence interval. (C) Kaplan-Meier curves following ICI treatment for NHW (N = 1,135) and NHB patients (N = 91) from MSKCC. (D) Significance determined by log-rank test as function of NLR threshold values in patients from MSKCC. Shaded region indicates standard deviation from cross-validation. NHW N = 1,135, NHB N = 91, Asian N = 96. (E–J) Kaplan-Meier curves following ICI treatments in patients from CCF with (E) lung cancer, NHW N = 2550, NHB N = 49; (F) breast cancer, NHW N = 352, NHB N = 102; (G) kidney cancer, NHW N = 508, NHB N = 46, (H) liver cancer, NHW N = 348, NHB N = 57; (I) cervical cancer, NHW N = 109, NHB N = 21; and (J) head and neck cancers, NHW N = 408, NHB N = 71. For all Kaplan-Meier curves, log-rank P values are shown with values split at upper tertile of cohort. HR, hazard ratio.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts